This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.

Start Date21 Jul 2022

Sponsor / Collaborator

Extend Biosciences, Inc.

[+3]

100 Clinical Results associated with Extend Biosciences, Inc.

0 Patents (Medical) associated with Extend Biosciences, Inc.

Literatures (Medical) associated with Extend Biosciences, Inc.

30 Apr 2024·JBMR Plus

Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism

Article

Author: Hales, Laura M ; Hall, Daniel B ; Kostyla, Caroline H ; Soliman, Tarik M

AbstractHypoparathyroidism, a deficiency of parathyroid hormone (PTH), results in hypocalcemia, hyperphosphatemia, and hypercalciuria. The disease is poorly controlled by calcium and vitamin D supplements or native PTH(1-84) replacement therapy. A version of PTH is being developed using D-VITylation technology, whereby vitamin D is conjugated to a therapeutic peptide, which confers a long plasma half-life by virtue of binding to the abundant vitamin D binding protein (DBP). D-VITylation of PTH caused no reduction in activity at the PTHR1 receptor, and resulted in a plasma elimination half-life of 7–15 h in rats and 24–32 h in cynomolgus monkeys. Analysis of steady-state pharmacokinetics as a function of dose showed flat profiles with smaller peak:trough ratios at low doses, indicative of slower subcutaneous absorption. In thyroparathyroidectomized (TPTx) rats, PTH(1-34)-vitamin D conjugates restored serum calcium and phosphate levels into the normal range over the 24 h dosing period, and increased bone turnover markers and reduced bone mineral density. Urinary calcium was initially elevated, but normalized by the end of treatment on day 27. In healthy monkeys, a single dose of PTH(1-34)-vitamin D conjugates elevated serum calcium levels above the normal range for a period of 24–48 h while simultaneously reducing urinary calcium. Therefore, the lead compound, EXT608, is a promising candidate as a therapeutic that can truly mimic the endogenous activity of PTH and warrants further study in patients with hypoparathyroidism.

01 Jun 2023·Journal of Cachexia, Sarcopenia and Muscle

EXT418, a novel long‐acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice

Article

Author: Breckheimer, Beatrice A ; Caeiro, Lucas ; Strait, Lena ; Lee, Ian In-Gi ; Hales, Laura M ; Rybachok, Artur ; Garcia, Jose M ; Christiani, Anthony ; Chen, Amanda ; Anderson, Barbara ; Dacek, Elizabeth ; Kostyla, Caroline H ; Krumm, Kora ; Soliman, Tarik M ; Kerr, Haiming L ; Hall, Daniel B ; Irwin, Brynn ; Jiang, Alice Siyi

AbstractBackgroundGhrelin is a potential therapy for cachexia due to its orexigenic properties and anabolic effects on muscle and fat. However, its clinical use is limited by the short half‐life of active (acylated) ghrelin (~11 min in humans). EXT418 is a novel long‐acting, constitutively active ghrelin analog created by covalently linking it to a vitamin D derivative. Here, we evaluated the effects and mechanisms of action of EXT418 on Lewis lung carcinoma (LLC)‐induced cachexia in mice.MethodsMale C57BL/6J mice (5‐ to 7‐month‐old) were implanted with 1 × 106 heat‐killed (HK) or live LLC cells. When the tumour was palpable, mice were injected with vehicle (T + V) or EXT418 daily (T + 418 Daily, 0.25 mg/kg/day) or every other day (T + 418 EOD, 0.5 mg/kg/EOD) for up to 14 days, whereas HK‐treated mice were given vehicle (HK + V). Subsets of T + 418 Daily or EOD‐treated mice were pair‐fed to the T + V group. Body composition and grip strength were evaluated before tumour implantation and at the end of the experiment. Molecular markers were probed in muscles upon termination.ResultsIn tumour‐bearing mice, administration of EXT418 daily or EOD partially prevented weight loss (T + V vs. T + 418 Daily, P = 0.030; and vs. T + 418 EOD, P = 0.020). Similar effects were observed in whole body fat and lean body mass. Grip strength in tumour‐bearing mice was improved by EXT418 daily (P = 0.010) or EOD (P = 0.008) administration compared with vehicle‐treated mice. These effects of EXT418 on weight and grip strength were partially independent of food intake. EXT418 daily administration also improved type IIA (P = 0.015), IIB (P = 0.037) and IIX (P = 0.050) fibre cross‐sectional area (CSA) in tibialis anterior (TA) and EXT418 EOD improved CSA of IIB fibres in red gastrocnemius (GAS; P = 0.005). In skeletal muscles, tumour‐induced increases in atrogenes Fbxo32 and Trim63 were ameliorated by EXT418 treatments (TA and GAS/plantaris, PL), which were independent of food intake. EXT418 administration decreased expression of the mitophagy marker Bnip3 (GAS/PL; P ≤ 0.010). Similar effects of EXT418 EOD were observed in p62 (GAS/PL; P = 0.039). In addition, EXT418 treatments ameliorated the tumour‐induced elevation in muscle Il6 transcript levels (TA and GAS/PL), independently of food intake. Il‐6 transcript levels in adipose tissue and circulating IL‐10 were elevated in response to the tumour but these increases were not significant with EXT418 administration. Tumour mass was not altered by EXT418.ConclusionsEXT418 mitigates LLC‐induced cachexia by attenuating skeletal muscle inflammation, proteolysis, and mitophagy, without affecting tumour mass and partially independent of food intake.

D-VITylation: Harnessing the biology of vitamin D to improve the pharmacokinetic properties of peptides and small proteins

Author: Soliman, Tarik M. ; Hales, Laura M. ; Vakkasoglu, Ahmet S. ; Hill, Caroline W. ; Hall, Daniel B.

Peptides can be potent and specific therapeutics, yet their small size leads to their rapid removal from the bloodstream by the kidneys, which severely limits their therapeutic potential.Although conjugation of small proteins to large polymers typically results in longer residence times, peptide-polymer conjugates often have a significant loss of biol. activity due to steric hindrance.Here, we improve the pharmacokinetics of peptide therapeutics by harnessing the biol. of vitamin D.We show that attachment of a vitamin D-based "carrier" mol. (D-VITylation) protects the conjugated peptide or protein from renal clearance by virtue of reversible binding to the serum-circulating vitamin D binding protein (DBP), without compromising bioactivity.By varying the conjugation site on vitamin D, the binding to DBP varies, with higher affinity constructs corresponding to a longer plasma half-life in vivo.We demonstrated the half-life extending potential of D-VITylation on two natural peptide hormones, ghrelin and insulin, and one small protein, FGF21.We observed increases in plasma half-life and decreases in clearance ranging from 10-100 fold copared to that of unmodified peptide.As proof-of-principle, we demonstrate that a vitamin D-insulin conjugate lowers blood glucose levels for nearly 24 h in a type 1 diabetic rat model.

News (Medical) associated with Extend Biosciences, Inc.

06 Oct 2024

·www.prnewswire.com

Israel Invited to UAE BioTech Symposium

On 6 October 2024, Dr. Kambiz Shekdar, PhD, retracted his personal ban on Israel in honor of a personal request by a former Rockefeller University classmate. The UAE BioTech Symposium is hosted at MasdarCity with registration at AmCham Abu Dhabi. BioTech Pioneers Worldwide are invited and welcomed to Abu Dhabi & Dubai, United Arab Emirates, November 6-8, 2024 to launch from Oil to Medicine. ABU DHABI, UAE, Oct. 6, 2024 /PRNewswire/ -- Rockefeller University BioTech Inventor Dr. Kambiz Shekdar, PhD, dedicates this event in loving memory of his mentor and doctoral thesis advisor, Dr. Günter Blobel, MD, PhD. "All guests are warmly invited to #RockBioTech for the benefit of science and humanity!" says Dr. Kambiz. Continue Reading Dr. Kambiz is Chairman of the UAE BioTech Symposium. Photo: Lesther @GalleriaMall. The BioTech pioneer's sole personal invitation recorded at Abrahamic Family House on October 6, 2024 is contained at the top of his personal link tree account as Chairman of the UAE BioTech Symposium. Dr.Kambiz's two-part "interview" with Emirati leadership "to get the job" to lead all interested stakeholders to go "from Oil to Medicine, Inshallah and Yallah!" will be posted at his personal portal by October 7, 2024. For more information go to: About UAE BioTech Symposium Chairman Dr. Kambiz Shekdar, PhD From invention at The Rockefeller University to IPO at New York Stock Exchange to scale-up drug discovery for jointly owned Made-in-Abu-Dhabi IP in the U.A.E., Dr. Kambiz Shekdar is the first U.S. Biotech Abu Dhabi Golden Visa Inventor transitioning to the U.A.E. Dr. Shekdar, PhD invented Chromovert® Technology while he was a graduate doctoral student in the laboratory of his mentor, the late Nobel laureate & King Faisal Prize winner Dr. Günter Blobel, MD, PhD. at The Rockefeller University in New York City. For more than 20 years, Dr. Shekdar has been pursuing applications of the same platform technology, now including pursuing the creation of a joint venture with Emirati stakeholders to implement the by-now validated research engine as part of a national-level public-private partnership for drug discovery at scale in the U.A.E. Dr. Shekdar is also a member of the Abu Dhabi, UAE chapter of American Chambers of Commerce where he is Founding Chairman of the AmCham Abu Dhabi BioTech Committee. About UAE BioTech Symposium UAE BioTech Symposium in partnership with the AmCham Abu Dhabi BioTech Committee and Masdar City will host quarterly panel discussions and lab tours in Abu Dhabi, Dubai and roadshow destinations throughout the GCC and Middle East. The events are free with attendance limited to prioritize U.S. and international BioTech owners and executives. Program details will be posted online in Arabic and in English as registration for each event goes live via the AmCham Abu Dhabi website. Arabic site for scientific program: English site for scientific program: About AmCham BioTech Committee The AmCham BioTech Committee was formed to establish a BioTech sector in Abu Dhabi with a focus on promoting opportunities for U.S. BioTech companies with a vision to be a thought leader and facilitator for U.S. corporate interests in the emerging BioTech sector in Abu Dhabi and throughout the Middle East. Since its founding, the BioTech committee has seen a notable uptick in interest from U.S.-based companies seeking to broaden their service offerings within the region. AmCham BioTech Committee founding members include Seconcell Bio, Intelligenix Advanced Diagnostics, Extend Biosciences, Halia Therapeutics and Jones Lang LaSalle Inc (JLL). CONTACT: Kambiz Shekdar, +971585820175 SOURCE Secondcell Bio, LLC; UAE BioTech Symposium WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

18 Sep 2024

·www.prnewswire.com

Secondcell Bio to Chair UAE BioTech Symposium in Masdar City, Abu Dhabi

The UAE BioTech Symposium will be hosted in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City The UAE BioTech Symposium will attract U.S. and international BioTech owners and executives exploring opportunities in the rapidly growing BioTech sector in Abu Dhabi The inaugural symposium will be followed by quarterly events with Roadshow destinations across the Middle East ABU DHABI, UAE, Sept. 18, 2024 /PRNewswire/ -- Secondcell Bio, a U.S. BioTech company scaling-up the its platform technology invented at The Rockefeller University in the United Arab Emirates, is pleased to invite U.S. and international BioTech owners and executives to participate in the inaugural UAE BioTech Symposium, in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City, taking place on November 6-8, 2024 in Masdar City, Abu Dhabi. Further details regarding the symposium and registration information may be found at . Continue Reading Competitiveness Talks Series at IRENA at Masdar City in February, 29, 2024. Masdar City will host all quarterly editions of the UAE BioTech Symposium in partnership with AmCham Abu Dhabi's BioTech Committee. Registration is free for qualified BioTech entrepreneurs new to the UAE market. To learn more visit . Masdar City in February, 29, 2024. (PRNewsfoto/UAE BioTech Symposium,Secondcell Bio, LLC) (PRNewsfoto/UAE BioTech Symposium,Secondcell Bio, LLC) The exclusive event focusing on advancing the biotechnology sector in Abu Dhabi, UAE is expected to attract approximately 150 qualified attendees interested in exploring opportunities in the rapidly growing BioTech and Life Sciences sector in the UAE. The symposium will offer an unparalleled platform to foster collaboration, innovation, growth and catalyze progress within the sector among entrepreneurs, researchers, governmental representatives and strategic investors. The inaugural symposium will be followed by quarterly events at destinations across the Middle East. "Abu Dhabi and Dubai attract the best of the best worldwide. Our forum is for BioTech owners and company builders. Join the adventure, #comeridewithme!" says Dr. Kambiz Shekdar, Chairman of the event and recipient of the first BioTech Inventor Golden Visa via a nomination from Abu Dhabi Competitive Office (COAD) who has transitioned to Abu Dhabi with support from Abu Dhabi Investment Office (ADIO)/Abu Dhabi Residents Office (ADRO), " If even the UAE invests a tiny fraction of its wealth, we can move from Oil to Medicine." The symposium will be held at Masdar City, a pioneering sustainable urban community and world-class business and technology hub that has cultivated a thriving ecosystem of leading global organizations dedicated to evolving research and innovation: As the leading Life Sciences cluster hub in Abu Dhabi, Masdar City is proud to host a rapidly growing number of 55 companies across key clusters such as Basic Research, Pre-Clinical Research, Clinical Trials, and Logistics and Service Delivery. Pioneering organizations like the region's first Biobank, Attentive Sciences, G42, Insilico Medicine and the Emirates Drug Establishment are part of our growing ecosystem have chosen Masdar City due to its supportive ecosystem which contributes to cutting-edge advancements in the life sciences sector industry. In close collaboration with key government entities such as the Department of Health (DOH), the Abu Dhabi Investment Office (ADIO), and the Abu Dhabi Department of Economic Development (ADDED), we are fully aligned with Abu Dhabi's vision for a knowledge-based economy. Masdar City Free Zone offers the right ecosystem, with unparalleled incentives, a strategic location, and a dynamic environment that empowers businesses to excel and deliver lasting impact both locally and globally. United States Ambassador to the United Arab Emirates Martina Strong, whom Dr. Shekdar first met at AmCham Abu Dhabi's ADIPEC Kick-Off Dinner in 2023, has expressed her possible interest in making our US-UAE initiative an 'ABC' (America, Britain, Canada) initiative. UAE BioTech Symposium wishes to go one step further: We invite BioTech pioneers from around the world to come join us as the exciting new BioTech and Life Sciences sector takes root and flourishes in Abu Dhabi and throughout the region. AmCham Abu Dhabi CEO, Liz Beneski will provide opening remarks for the symposium, which is the first forum of its kind in the region. The symposium will provide attendees the opportunity to hear from distinguished international experts as well as founding members of the AmCham Abu Dhabi BioTech Committee. Key discussion topics will include growth of the BioTech sector across various regions, Emirati genomic research initiatives and the future of medicine in the UAE. Networking opportunities will be available for BioTech sector leaders to gather, discuss and explore potential areas of collaboration along with exclusive immersive visits to local laboratories and research hospitals in Abu Dhabi and Dubai for an up-close view of the cutting-edge capabilities and facilities in the UAE. "It has been a privilege working alongside Dr. Shekdar where his expertise and genuine altruistic dedication to advancing science for the benefit of all humanity have been invaluable in inspiring our team to advance our organizational objectives," says Fabienne Duchini of Secondcell Bio, "Under Dr. Shekdar's visionary leadership, the symposium will offer novel insights and a compelling vision for the future of BioTech. I hope you will join us to see all of what the UAE has to offer." Several UAE government-linked entities will have information available about their services and business incentives for companies looking to expand to the UAE, including Masdar City, Abu Dhabi Investment Office, Abu Dhabi Residents Office and [LIST-IN-FORMATION]. The symposium will offer an optional weekend program featuring a variety of cultural, leisure and lifestyle experiences in Abu Dhabi and Dubai. The weekend activities have been selected by luxury travel agency 2xceed Destination Management to enable participants to explore all that these two Emirati destinations have to offer outside the official program. We are grateful for the support of our generous corporate sponsors and exhibitors. Sponsors include Halia Therapeutics and Innova Therapeutics. International knowledge partners and corporate exhibitors include Jones Lang LaSalle Inc. (JLL), AtkinsRéalis, GRÜNECKER Patent Attorneys and Attorneys-at-Law, Sartorius Stedim Biotech GmbH, BioTech Clusters and university technology transfer offices [LIST-IN-FORMATION]. PRESS BRIEFINGS We invite members of the press to learn more. Private one-on-one briefings are available for scheduling as follows: 1) Members of UAE and GCC press: 10am to 8pm, Monday September 16, 2024, 10am to 8pm, Monday September 23, 2024 and 10am to 8pm, Monday October 7, 2024, GCC Time Zone 2) Business & technology press: 7am to 5pm, Tuesday October 8, 2024, EST Time Zone 3) All members of the press: 10am to 10pm, Wednesday October 9, 2024, GCC Time Zone To schedule a private one-on-one press briefing, please contact Fabienne Duchini at [email protected]. At a closed-door press briefing, Dr. Shekdar will share his personal experience navigating business opportunities in the UAE, adapting to the culture and his impression of the opportunities and challenges for others considering the move. We encourage members of the media including business press, U.S. and local outlets to join for a firsthand account of his experience pioneering a new sector of the knowledge based economy in the most mature market in the Arab Gulf States. Additional information for members of the press is available here: About UAE BioTech Symposium UAE BioTech Symposium in partnership with the AmCham Abu Dhabi BioTech Committee and Masdar City will host quarterly panel discussions and lab tours in Abu Dhabi, Dubai and roadshow destinations throughout the GCC and Middle East. The events are free with attendance limited to prioritize U.S. and international BioTech owners and executives. Program details will be posted online in Arabic and in English as registration for each event goes live via the AmCham Abu Dhabi website. Arabic site for scientific program: English site for scientific program: About AmCham Abu Dhabi AmCham Abu Dhabi (the trademark of the American Business Group of Abu Dhabi) is a member of the global network of American Chambers of Commerce. Active since 1986, AmCham Abu Dhabi's Mission is to promote commerce, investment, and goodwill between its membership, the United States of America and the United Arab Emirates. Our vision is to be an innovative organization creating trusted commercial partnerships that broaden U.S. - U.A.E. relationships. AmCham Abu Dhabi is an independent, not-for-profit association, comprised of Fortune 500 corporations, small and medium sized companies and prominent business leaders and entrepreneurs. For more information, visit: About Masdar City Masdar City is a pioneering sustainable urban community, a world-class business and technology hub, and a "green-print" for cities that want to be part of the solution to climate change. With one of the largest clusters of LEED Platinum buildings in the world, we are dedicated to creating a new kind of city, a new way of working and living, and a more sustainable future for everyone. The Masdar City Free Zone is a diverse, innovative, and ambitious group of over 1,000 organizations that benefit from comprehensive business support as well as the city's rich ecosystem. Tenants include the International Renewable Energy Agency (IRENA), the UAE Space Agency, Siemens Energy, G42, the Advanced Technology Research Council, several Fortune 500 companies, and the Mohamed bin Zayed University of Artificial Intelligence. The Masdar City Free Zone also includes The Catalyst, a clean-tech start-up investor powered by both Masdar City and BP. Masdar City hosts a growing residential community and has piloted two generations of autonomous vehicles. It also manages the Masdar Green REIT, a real estate investment trust dedicated to investing in sustainable real estate assets. Currently the Masdar Green REIT is worth nearly AED 2.9 billion. About AmCham Abu Dhabi BioTech Committee The AmCham BioTech Committee was formed to establish a BioTech sector in Abu Dhabi with a focus on promoting opportunities for U.S. BioTech companies with a vision to be a thought leader and facilitator for U.S. corporate interests in the emerging BioTech sector in Abu Dhabi and throughout the Middle East. Since its founding, the BioTech committee has seen a notable uptick in interest from U.S.-based companies seeking to broaden their service offerings within the region. AmCham BioTech Committee founding members include Seconcell Bio, Intelligenix Advanced Diagnostics, Extend Biosciences, Halia Therapeutics and Jones Lang LaSalle Inc (JLL). AMCHAM ABU DHABI BIOTECH COMMITTEE FOUNDING MEMBERS About Secondcell Bio Secondcell Bio™ is building public-private partnerships worldwide to scale-up the demonstrated and largely automated platform biotechnology originating from The Rockefeller University. The company was formed by Dr. Kambiz Shekdar, PhD, inventor of Chromovert® Technology. Secondcell Bio owns Chromovert® Technology. About Intelligenix Advanced Diagnostics Intelligenix Advanced Diagnostics is a biotechnology company currently developing novel diagnostic and therapeutic technology for breast and prostate cancer under the rubrics of personalized and precision medicine. Intelligenix AD is developing cutting-edge, targeted therapeutics and companion diagnostic tests that encompass five critical areas: 1) determining cancer risk, 2) cancer early detection and diagnosing, 3) determining the best course of treatment, 4) molecular-based therapeutics, and 5) monitoring treatment effectiveness. Intelligenix Advanced Diagnostic's technology aims to significantly advance cancer disease management via its impressive patented technology platform, which covers these critical areas for precision medicine and ultimately improves patient outcomes and survival rates. About Extend Biosciences Extend Biosciences Inc. is a clinical stage biotechnology company developing a novel drug delivery platform technology (D-VITylation®) that significantly improves the pharmacokinetic properties of peptides and proteins. The Company's lead D-VITylated drug candidate, EXT608, targets the rare disease Hypoparathyroidism (HPT) characterized by inappropriately low circulating levels of parathyroid hormone (PTH). EXT608 is being developed as a subcutaneously self-administered once-weekly dosing regimen for improved patient compliance and superior efficacy. Phase 2 trials in patients are underway. About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neuroinflammation, metabolic diseases, and chronic inflammation. Through a unique approach targeting inflammatory pathways, Halia aims to deliver groundbreaking treatments to improve patient outcomes in areas of high unmet medical need. About Jones Lang LaSalle Inc. (JLL) / JLL MENA / JLL Healthcare and Lifsciences For over 200 years, JLL (NYSE: JLL), a leading global commercial real estate and investment management company, has helped clients buy, build, occupy, manage and invest in a variety of commercial, industrial, hotel, residential and retail properties. A Fortune 500 company with annual revenue of $20.8 billion and operations in over 80 countries around the world, our more than 108,000 employees bring the power of a global platform combined with local expertise. Driven by our purpose to shape the future of real estate for a better world, we help our clients, people and communities SEE A BRIGHTER WAYSM. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit JLL MEA. Across the Middle East and Africa (MEA) JLL is a leading player in the real estate and hospitality services markets. The firm has worked in 35 countries across the region and employs over 1900 internationally qualified professionals across its offices in Dubai, Abu Dhabi, Riyadh, Jeddah, Al Khobar, Cairo, Casablanca, Cape Town, Johannesburg and Nairobi. JLL Healthcare and Lifesciences. JLL's Healthcare and Life Sciences consulting team offers a global network of experts with extensive regional expertise. We provide best-in-class advisory services for companies in these sectors, including feasibility studies, market entry and expansion strategies, technical and commercial due diligence. Our comprehensive consulting services help clients navigate complex challenges in the healthcare and life sciences industries. AMCHAM ABU DHABI BIOTECH COMMITTEE NEW MEMBERS About Innova Therapeutics Innova Therapeutics is a biopharmaceutical company developing a monoclonal antibody (mAb) platform targeting a novel protein that is highly expressed in both solid and hematological cancers. Innova's platform technology is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, triple negative breast cancer, multiple myeloma and pancreatic cancer. Current cancer therapies only target either the tumors directly or one component of the tumor microenvironment, while the pathway targeted with our therapy impacts both the tumor and tumor microenvironment simultaneously through a common pathway. In addition, a diagnostic is in development which has the tremendous potential for early cancer detection, as well as a prognostic marker for assessing therapeutic benefit of treatments and assessment of potential reoccurrence of cancer. UAE BioTech Symposium Cultural, Tourism and Logistics Partner About 2xceed Destination Management 2xceed delivers bespoke luxury travel, event planning, and corporate services with a focus on exceptional local expertise in UAE and all Middle East, innovative itineraries, and VIP experiences. Their offerings include tailored holidays, special event access, meetings & incentives, congress management, and comprehensive event logistics, all while adhering to principles of sustainability and corporate social responsibility. SOURCE Secondcell Bio, LLC; UAE BioTech Symposium WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

16 Sep 2024

·www.prnewswire.com

Abu Dhabi to Host New Quarterly Forum to Attract U.S. BioTech Firms

The UAE BioTech Symposium will attract U.S. and international BioTech owners and executives new to exploring opportunities in the UAE market Secondcell Bio CEO Dr. Kambiz Shekdar will serve as symposium Chairman The UAE BioTech Symposium will be hosted in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City ABU DHABI, UAE, Sept. 16, 2024 /PRNewswire/ -- The UAE's leadership is heavily investing in its knowledge-based economy where expanding the BioTech sector is a top priority. The newly formed UAE BioTech Symposium will provide a forum for U.S. and international BioTech owners and executives exploring opportunities in the rapidly growing BioTech sector in Abu Dhabi and throughout the Middle East. Event registration will go live on AmCham Abu Dhabi's website this week. To learn more, go to the UAE BioTech Symposium page on LinkedIn at . Continue Reading Masdar City will host all quarterly editions of the UAE BioTech Symposium in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City, following a format for industry leaders pioneered at the Competitiveness Talks Series at IRENA at Masdar City in February, 29, 2024, pictured below. Photo credit: Masdar City. The symposium will be hosted in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City, taking place on November 6-8, 2024 at Masdar City, Abu Dhabi and Dubai, UAE, including roadshow destinations throughout the Arab Gulf States of the GCC to follow, including Saudi Arabia, Qatar and Kuwait. "I'm so happy to welcome my U.S. BioTech colleagues," says Secondcell Bio CEO, AmCham Abu Dhabi BioTech Committee Founding Chairman and UAE BioTech Symposium Chairman Dr. Kambiz Shekdar PhD, "At least 40 known to me plan to make their first trip to seriously explore business opportunities to witness firsthand what has captured my imagination. Welcome, colleagues, Marhaba!" Shekdar is the first U.S. BioTech inventor who has transitioned to the UAE. His journey started 2.5 years ago with his first trip to Dubai and Abu Dhabi. Shekdar recently moved to Abu Dhabi, upon being issued the prestigious United Arab Emirates Golden Visa under the Inventor category, becoming the first BioTech inventor to receive this coveted visa status. Secondcell Bio joined AmCham Abu Dhabi as the first BioTech corporate member in recognition of its support to help accelerate the emerging BioTech sector in the UAE. Recognizing that BioTech was a high priority for the UAE government, AmCham Abu Dhabi CEO Liz Beneski advocated for the creation of the AmCham Abu Dhabi BioTech Committee, where Shekdar serves as Founding Chairman. The mission of the BioTech Committee is to establish a BioTech sector in Abu Dhabi with a focus on promoting opportunities for U.S. BioTech companies in Abu Dhabi and throughout the Middle East, bringing together government, investor, corporate and academic stakeholders. As Founding Chairman of the BioTech Committee, recruiting additional U.S. BioTech companies to join was a priority task, where Shekdar has recruited five U.S. BioTech members and counting. All members of the BioTech Committee will be sharing their announcements at the event. UAE BioTech Symposium is anticipated to attract approximately 150 qualified attendees interested in exploring opportunities in the UAE by offering a forum to foster collaboration, innovation, growth and catalyze progress within the BioTech sector among entrepreneurs, researchers, governmental representatives and strategic investors. Attendees of the symposium will have the opportunity to hear from an esteemed group of internationally recognized speakers and government representatives, including Her Excellency Dr. Maryam Matar, Founder and Chairperson of UAE Genetic Diseases Association, who will share her expertise on "Rare Disease and Precision Medicine." Tanya Cole, Regional Senior Commercial Officer for GCC and Commercial Counselor for UAE at the United States Embassy in the UAE, who will present on "BioTech is the Future" at the opening reception. Dr. Patricia Morris, MS, PhD, former President of the Federation of American Societies for Experimental Biology (FASEB), an organization representing over 150,000 American experimental scientists through its member organizations, and Secondcell Bio Senior Scientific Health Policy Advisor, will discuss "BioTech Sector Growth in the United States of America." Director of the Columbia University Center for Human Longevity, Columbia University Medical Center Southworth Professor and Chairman Emeritus of Medicine and Secondcell Bio Chief Medical Advisor, Dr. Donald Landry, MD, PhD, will present on the topic of "Longevity" as part of a panel focused on "The Emirati Genome and Future of Medicine in the UAE." Also participating in this panel is John Rockefeller, JD, MPH, DrPH, Director of Research Foundation for Cure Initiatives and former board member of the Clinton Health Access Initiative, who will address "Medicine for the World" to make medicines available for all those in need worldwide by working with groups like Emirates Red Crescent. Ten members of the Secondcell Bio's team and advisors, including Dr. Particia Morris, MS, PhD, Dr. Donald Landry, MD, PhD, and Mr. John Rockefeller, JD, MPH, DrPH, will be accompanying Dr. Shekdar on the occasion of the UAE BioTech Symposium for additional meetings with UAE stakeholders regarding the creation of "Emiraticell Bio," a national level BioTech joint venture company with UAE partners to discover and commercialize "Made-in-Abu-Dhabi BioTech IP." Following seven trips to the UAE spending four months in the country in 2022 and 2023, Shekdar became convinced the UAE was the right place to scale up his technology. "It is the combination of innovations like ours plus the leadership, vision and scale of implementation as I've seen mastered only in the UAE that gives our partnership the potential to leap-frog the global industry," says Shekdar. We invite members of the press to learn more. Private one-on-one briefings are available for scheduling as follows:1) Members of UAE and GCC press: 10am to 8pm, Monday September 16, 2024, 10am to 8pm, Monday September 23, 2024 and 10am to 8pm, Monday October 7, 2024, GCC Time Zone 2) Business & technology press: 7am to 5pm, Tuesday October 8, 2024, EST Time Zone 3) All members of the press: 10am to 10pm, Wednesday October 9, 2024, GCC Time Zone To schedule a private one-on-one press briefing, please contact Fabienne Duchini at [email protected]. At a closed-door press briefing, Shekdar will share his personal experience navigating business opportunities in the UAE, adapting to the culture and his impression of the opportunities and challenges for others considering the move. We encourage members of the media including business press, U.S. and local outlets to join for a firsthand account of his experience pioneering a new sector of the knowledge based economy in the most mature market in the Arab Gulf States. Additional information on Dr. Shekdar's journey as the first U.S. BioTech inventor transitioning to the UAE is available via his editorial commentary in his column in Manhattan's community print newspaper WestView News and in his video series on YouTube series: Dr. Shekdar's "From Oil to Medicine" in WestView News: Dr. Shekdar's "From Oil to Medicine: China Gains" in WestView News: Dr. Shekdar's "From Oil to Medicine" video series on YouTube: About UAE BioTech Symposium UAE BioTech Symposium in partnership with the AmCham Abu Dhabi BioTech Committee and Masdar City will host quarterly panel discussions and lab tours in Abu Dhabi, Dubai and roadshow destinations throughout the GCC and Middle East. The events are free with attendance limited to prioritize U.S. and international BioTech owners and executives. Program details will be posted online in Arabic and in English as registration for each event goes live via the AmCham Abu Dhabi website. Arabic site for scientific program: English site for scientific program: About UAE BioTech Symposium Chairman Dr. Kambiz Shekdar, PhD From invention at The Rockefeller University to IPO at New York Stock Exchange to scale-up drug discovery for jointly owned Made-in-Abu-Dhabi IP in the U.A.E., Dr. Kambiz Shekdar is the first U.S. Biotech Abu Dhabi Golden Visa Inventor transitioning to the U.A.E. Dr. Shekdar, PhD invented Chromovert® Technology while he was a graduate doctoral student in the laboratory of his mentor, the late Nobel laureate & King Faisal Prize winner Dr. Gunter Blobel, MD, PhD. at The Rockefeller University in New York City. For more than 20 years, Dr. Shekdar has been pursuing applications of the same platform technology, now including pursuing the creation of a joint venture with Emirati stakeholders to implement the by-now validated research engine as part of a national-level public-private partnership for drug discovery at scale in the U.A.E. Dr. Shekdar is also a member of the Abu Dhabi, UAE chapter of American Chambers of Commerce where he is Founding Chairman of the AmCham Abu Dhabi BioTech Committee. About AmCham BioTech Committee The AmCham BioTech Committee was formed to establish a BioTech sector in Abu Dhabi with a focus on promoting opportunities for U.S. BioTech companies with a vision to be a thought leader and facilitator for U.S. corporate interests in the emerging BioTech sector in Abu Dhabi and throughout the Middle East. Since its founding, the BioTech committee has seen a notable uptick in interest from U.S.-based companies seeking to broaden their service offerings within the region. AmCham BioTech Committee founding members include Seconcell Bio, Intelligenix Advanced Diagnostics, Extend Biosciences, Halia Therapeutics and Jones Lang LaSalle Inc (JLL). About AmCham Abu Dhabi BioTech Committee Founding Chair Secondcell Bio Secondcell Bio™ is building public-private partnerships worldwide to scale-up the demonstrated and largely automated platform biotechnology originating from The Rockefeller University. The company was formed by Dr. Kambiz Shekdar, PhD, inventor of Chromovert® Technology. Secondcell Bio owns Chromovert® Technology. Biological science deals with the human cell. Cells that exactly mimic human disease are fundamental for discovery of new drugs. However, in a sea of cells engineered to model disease, only a tiny number are suitable. Detecting and isolating the optimal cells is extraordinarily difficult. Chromovert® facilitates the detection and purification of even exceedingly rare, desired cells. Applicable to any gene and any cell, the platform technology opens new applications in flavors and drug discovery, biologics manufacturing, cell and stem cell therapies, and crop engineering. The scientific publication of the technology is available at this link: SOURCE Secondcell Bio, LLC; UAE BioTech Symposium WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Extend Biosciences, Inc.

100 Translational Medicine associated with Extend Biosciences, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

EXT608	Hypoparathyroidism More	Phase 2
EXT418 ( GHSR )	Cachexia More	Phase 1 Clinical
EXT-607	Hypoparathyroidism More	Discontinued
EXT-055	Diabetes Mellitus More	Discontinued
EXT-700	Diabetes Mellitus More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis